Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07315061) titled 'A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis' on Dec. 18, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: InventisBio Co., Ltd
Condition:
PsA (Psoriatic Arthritis)
Intervention:
Drug: D-2570
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: December 22, 2025
Target Sample Size: 222
Countries of Recruitment:
China
To know more, visi...